Business Description
Ondine Biomedical Inc
NAICS : 541714
SIC : 3741
ISIN : CA68234M2058
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.48 | |||||
Equity-to-Asset | 0.01 | |||||
Debt-to-Equity | 18.27 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -66.23 | |||||
Beneish M-Score | -2.22 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.2 | |||||
3-Year EBITDA Growth Rate | 1.6 | |||||
3-Year EPS without NRI Growth Rate | 4.4 | |||||
3-Year FCF Growth Rate | -29.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 23.51 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 109.37 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 85.66 | |||||
9-Day RSI | 72.29 | |||||
14-Day RSI | 64.26 | |||||
6-1 Month Momentum % | 16.67 | |||||
12-1 Month Momentum % | -41.36 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.8 | |||||
Quick Ratio | 0.48 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 645.47 | |||||
Days Sales Outstanding | 48.97 | |||||
Days Payable | 647.39 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | -13.72 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.96 | |||||
Operating Margin % | -893.57 | |||||
Net Margin % | -873.24 | |||||
FCF Margin % | -769.42 | |||||
ROE % | -670.11 | |||||
ROA % | -246.17 | |||||
ROIC % | -491.02 | |||||
3-Year ROIIC % | -2.64 | |||||
ROC (Joel Greenblatt) % | -1465.07 | |||||
ROCE % | -594.89 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 21.25 | |||||
PB Ratio | 17 | |||||
Price-to-Tangible-Book | 6.35 | |||||
EV-to-EBIT | -2.8 | |||||
EV-to-Forward-EBIT | -3.7 | |||||
EV-to-EBITDA | -2.92 | |||||
EV-to-Forward-EBITDA | -1.42 | |||||
EV-to-Revenue | 24.41 | |||||
EV-to-Forward-Revenue | 8.48 | |||||
EV-to-FCF | -3.18 | |||||
Earnings Yield (Greenblatt) % | -35.71 | |||||
FCF Yield % | -30.85 |